CureVac (NASDAQ:CVAC) Shares Up 2.6%

Shares of CureVac (NASDAQ:CVAC) shot up 2.6% on Thursday . The company traded as high as $55.20 and last traded at $55.09. 217 shares were traded during trading, a decline of 100% from the average session volume of 1,152,690 shares. The stock had previously closed at $53.67.

A number of research firms have weighed in on CVAC. Berenberg Bank set a $123.00 price objective on shares of CureVac and gave the stock a “buy” rating in a report on Thursday, July 1st. Zacks Investment Research raised CureVac from a “sell” rating to a “hold” rating in a research report on Friday, July 16th. Guggenheim assumed coverage on CureVac in a research report on Monday, May 3rd. They issued a “buy” rating for the company. Evercore ISI reissued a “buy” rating on shares of CureVac in a research report on Monday, July 5th. Finally, Bank of America cut CureVac from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Thursday, June 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $80.80.

The company has a debt-to-equity ratio of 0.04, a current ratio of 5.61 and a quick ratio of 5.55. The firm has a market cap of $10.17 billion and a P/E ratio of -49.19. The stock’s 50 day simple moving average is $84.70.

Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaMark Advisors LLC acquired a new stake in shares of CureVac during the first quarter worth $30,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of CureVac during the first quarter worth $42,000. Citigroup Inc. lifted its holdings in shares of CureVac by 565.0% during the fourth quarter. Citigroup Inc. now owns 665 shares of the company’s stock worth $54,000 after purchasing an additional 565 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of CureVac during the first quarter worth $83,000. Finally, swisspartners Ltd. acquired a new stake in shares of CureVac during the first quarter worth $219,000. 7.15% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile (NASDAQ:CVAC)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.

Read More: Coverage Ratio

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.